Literature DB >> 25047526

Drug-induced hyperkalemia.

Chaker Ben Salem1, Atef Badreddine, Neila Fathallah, Raoudha Slim, Houssem Hmouda.   

Abstract

Hyperkalemia is a common clinical condition that can be defined as a serum potassium concentration exceeding 5.0 mmol/L. Drug-induced hyperkalemia is the most important cause of increased potassium levels in everyday clinical practice. Drug-induced hyperkalemia may be asymptomatic. However, it may be dramatic and life threatening, posing diagnostic and management problems. A wide range of drugs can cause hyperkalemia by a variety of mechanisms. Drugs can interfere with potassium homoeostasis either by promoting transcellular potassium shift or by impairing renal potassium excretion. Drugs may also increase potassium supply. The reduction in renal potassium excretion due to inhibition of the renin-angiotensin-aldosterone system represents the most important mechanism by which drugs are known to cause hyperkalemia. Medications that alter transmembrane potassium movement include amino acids, beta-blockers, calcium channel blockers, suxamethonium, and mannitol. Drugs that impair renal potassium excretion are mainly represented by angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, direct renin inhibitors, nonsteroidal anti-inflammatory drugs, calcineurin inhibitors, heparin and derivatives, aldosterone antagonists, potassium-sparing diuretics, trimethoprim, and pentamidine. Potassium-containing agents represent another group of medications causing hyperkalemia. Increased awareness of drugs that can induce hyperkalemia, and monitoring and prevention are key elements for reducing the number of hospital admissions, morbidity, and mortality related to drug-induced hyperkalemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25047526     DOI: 10.1007/s40264-014-0196-1

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  129 in total

Review 1.  Electrolyte disturbances associated with commonly prescribed medications in the intensive care unit.

Authors:  Mitchell S Buckley; Jaclyn M Leblanc; Michael J Cawley
Journal:  Crit Care Med       Date:  2010-06       Impact factor: 7.598

2.  Hyperkalemia caused by penicillin.

Authors:  A Thiele; Habib U Rehman
Journal:  Am J Med       Date:  2008-08       Impact factor: 4.965

Review 3.  Drug-induced hyperkalemia: old culprits and new offenders.

Authors:  M A Perazella
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

Review 4.  The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.

Authors:  Erika B Rangel
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-09-17       Impact factor: 4.481

5.  Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy.

Authors:  Giampiero Giovacchini; Guillaume Nicolas; Heike Freidank; Thomas L Mindt; Flavio Forrer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-07       Impact factor: 9.236

6.  Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis.

Authors:  Matthew R Weir; Christopher Bush; David R Anderson; Jack Zhang; Deborah Keefe; Andrew Satlin
Journal:  J Am Soc Hypertens       Date:  2007 Jul-Aug

7.  Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals.

Authors:  Pernelle Noize; Haleh Bagheri; Geneviève Durrieu; Françoise Haramburu; Nicholas Moore; Patrick Giraud; Michel Galinier; Jacques Pourrat; Jean-Louis Montastruc
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-03-16       Impact factor: 2.890

8.  Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues.

Authors:  Raffaella Barone; Stanislas Pauwels; Joëlle De Camps; Eric P Krenning; Larry K Kvols; M Charles Smith; Hakim Bouterfa; Olivier Devuyst; François Jamar
Journal:  Nephrol Dial Transplant       Date:  2004-07-13       Impact factor: 5.992

9.  Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Authors:  Y Miao; D Dobre; H J Lambers Heerspink; B M Brenner; M E Cooper; H-H Parving; S Shahinfar; D Grobbee; D de Zeeuw
Journal:  Diabetologia       Date:  2010-09-30       Impact factor: 10.122

Review 10.  Antihypertensive therapy and its effects on potassium homeostasis.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-01       Impact factor: 3.738

View more
  24 in total

Review 1.  Tolerability of Antihypertensive Medications in Older Adults.

Authors:  Thiruvinvamalai S Dharmarajan; Lekshmi Dharmarajan
Journal:  Drugs Aging       Date:  2015-10       Impact factor: 3.923

2.  The clinical relevance of drug-drug interaction between co-trimoxazole and sacubitril/valsartan treatment in a heart failure patient: a case report and overview of mechanisms and management in clinical practice.

Authors:  Eleni S Nakou; Maria E Marketou; Panos E Vardas; Fragiskos I Parthenakis
Journal:  Clin Res Cardiol       Date:  2018-01-15       Impact factor: 5.460

3.  Epidemiology of hyperkalemia in CKD patients under nephrological care: a longitudinal study.

Authors:  Vincenzo Panuccio; Daniela Leonardis; Rocco Tripepi; Maria Carmela Versace; Claudia Torino; Giovanni Tripepi; Graziella D'Arrigo; Francesca Mallamaci; Carmine Zoccali
Journal:  Intern Emerg Med       Date:  2021-02-11       Impact factor: 3.397

Review 4.  Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.

Authors:  Calvin J Meaney; Mario V Beccari; Yang Yang; Jiwei Zhao
Journal:  Pharmacotherapy       Date:  2017-03-10       Impact factor: 4.705

Review 5.  Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function.

Authors:  Raquel Esteras; Maria Vanessa Perez-Gomez; Laura Rodriguez-Osorio; Alberto Ortiz; Beatriz Fernandez-Fernandez
Journal:  Ther Adv Drug Saf       Date:  2015-08

6.  Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.

Authors:  Yshai Yavin; Traci A Mansfield; Agata Ptaszynska; Kristina Johnsson; Shamik Parikh; Eva Johnsson
Journal:  Diabetes Ther       Date:  2016-01-12       Impact factor: 2.945

Review 7.  Potassium Metabolism and Management in Patients with CKD.

Authors:  Shinsuke Yamada; Masaaki Inaba
Journal:  Nutrients       Date:  2021-05-21       Impact factor: 5.717

Review 8.  A brief review on in vivo models for Gouty Arthritis.

Authors:  Tulsi Patil; Arun Soni; Sanjeev Acharya
Journal:  Metabol Open       Date:  2021-06-14

9.  Association Between Long-Term Use of Non-steroidal Anti-inflammatory Drugs and Hyperkalemia in Diabetic Patients.

Authors:  Fnu Sahil; Jatender Kumar; Gul Raiz; Naila S Bhutto; Hamza Tahir; Zauraiz Anjum; Sidra Naz; Amber Rizwan; Maha Jahangir; Sania Muhammad Shehzad
Journal:  Cureus       Date:  2021-06-14

10.  Improvement of surface ECG recording in adult zebrafish reveals that the value of this model exceeds our expectation.

Authors:  Chi Chi Liu; Li Li; Yun Wah Lam; Chung Wah Siu; Shuk Han Cheng
Journal:  Sci Rep       Date:  2016-04-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.